Myelodysplastic Syndrome (MDS)

- **Lower-Risk**
  - IRB# 15214
    - Phase 1a/1b study of Oral INCB052793 (Jak1/Jak2 inhibitor)
  - IRB# 16338
    - Aileron Phase 1/1b ALRN-6924 (Wild Type TP53)
  - IRB# 16964
    - Study coming soon
- **Intermediate**
  - IRB# 16867
    - Study coming soon (treatment naive high risk MDS)
  - IRB# 15977
    - Non Treatment National MDS Study (ECOG/ACRIN)
  - IRB# 17379
    - Study coming soon (Not candidates for standard induction therapy)
- **High Risk**
  - **New MDS**
    - IRB# 16964
      - Study coming soon
  - **Relapsed/Refractory**
    - IRB# 15214
      - Phase 1a/1b study of Oral INCB052793 (Jak1/Jak2 inhibitor)
    - IRB# 11076
      - Phase I with LOR-253
    - IRB# 16964
      - Study coming soon
    - IRB# 16896
      - Study coming soon
    - IRB# 16338
      - Aileron Phase 1/1b ALRN-6924 (Wild Type TP53)
    - IRB# 17379
      - Study coming soon (Not candidates for standard induction therapy)
- **Treatment Related**
  - IRB# 15993
    - HLA-A2.0 and PRAME (relapsed/refractory MDS)

http://www.ohsu.edu/research/rda/so/knight.php